Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEG6498 in Advanced Solid Tumors
NCT07244835Phase 1Recruiting
- Sponsor
- Degron Therapeutics
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DEG6498 in solid tumor and hepatocellular carcinoma (HCC), sponsored by Degron Therapeutics. Primary endpoints: Incidence of dose limiting toxicity at 4 weeks and Incidence of adverse events and serious adverse events. Started Nov 2025; status: recruiting.
02
Drugs
DEG6498
03
Conditions
solid tumorhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07244835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07244835.